手术平台是否影响复发和生存?多孔、单孔与机器人辅助腹腔镜在子宫内膜癌手术中应用的研究
这项多中心、单机构回顾性队列研究纳入2009至2015年接受微创手术的1150例子宫内膜癌患者,比较机器人辅助腹腔镜(n=652)、多孔腹腔镜(n=214)和单孔腹腔镜(n=284)的无进展生存和总生存。结果显示三种平台在2、3、5年无进展生存和总生存上均无差异(P=.93和P=.99),多因素分析中手术方式不影响生存,而年龄>65岁和晚期疾病与总生存下降相关。
要点
- 机器人辅助、多孔和单孔腹腔镜三组在2、3、5年无进展生存和总生存均无差异。
- 多因素分析显示手术平台不影响总生存或无进展生存。
- 年龄>65岁和晚期疾病与总生存下降相关。
核心结论
- 在这项回顾性队列中,机器人辅助腹腔镜、单孔腹腔镜或多孔腹腔镜行子宫内膜癌手术的女性无进展生存或总生存无差异。
研究设计与样本
- 多中心、单机构回顾性队列研究,纳入2009至2015年诊断为子宫内膜癌并接受微创手术的女性。
- 共1150例,其中机器人辅助腹腔镜652例、多孔腹腔镜214例、单孔腹腔镜284例。
- 收集中位年龄62.0岁、中位体重指数33.5 kg/m2及病理、辅助治疗和疾病状态等资料。
- 采用Pearson χ2和Fisher精确检验评估结局危险因素,Kaplan-Meier估计和Cox比例风险模型评估进展或死亡时间差异,并进行多因素回归分析。
主要发现
- 全队列2、3、5年无进展生存:多孔腹腔镜94.2%、91.4%、87.4%,机器人辅助腹腔镜94.5%、92.9%、88.8%,单孔腹腔镜93.6%、91.2%、90.0%(P=.93)。
- 全队列2、3、5年总生存:多孔腹腔镜94.4%、91.8%、91.8%,机器人辅助腹腔镜95.6%、93.4%、90.7%,单孔腹腔镜95.0%、93.1%、91.8%(P=.99)。
- IA和IB期患者2、3、5年无进展生存:多孔腹腔镜94.2%、91.4%、87.4%,机器人辅助腹腔镜94.5%、92.9%、88.8%,单孔腹腔镜93.6%、91.2%、90.0%(P=.93)。
- I期患者2、3、5年总生存:多孔腹腔镜96.2%、95.0%、95.0%,机器人辅助腹腔镜96.6%、95.4%、93.3%,单孔腹腔镜96.6%、95.0%、93.4%(P=.89)。
- 多因素分析中,与多孔腹腔镜相比,机器人辅助腹腔镜风险比1.28(P=.50),单孔腹腔镜风险比0.84(P=.68),手术方式不影响总生存或无进展生存;年龄>65岁风险比5.42(P<.001)和晚期疾病(P=.003)与总生存下降相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Minimally invasive hysterectomy is the standard of care in the majority of women diagnosed with endometrial cancer via robotic-assisted, multiport, and single-port laparoscopy technology. Although safe and efficacious, it is unclear how oncologic outcomes are impacted by surgical platform. OBJECTIVE: To identify differences in progression-free survival and overall survival in women undergoing minimally invasive surgery for endometrial cancer staging via either multiport, single-port, or robotic-assisted laparoscopy. STUDY DESIGN: A multicenter, single-institution retrospective cohort study was performed in women with a diagnosis of endometrial cancer who underwent minimally invasive surgery from 2009 to 2015. Data were collected for demographics, pathologic information, adjuvant treatment, and disease status. Pearson χ2 and Fisher exact tests were used to evaluate risk factors for outcomes, Kaplan-Meier estimates and Cox proportional hazards were used to evaluate differences in time to progression or death, and multivariate regression analysis was performed. RESULTS: In total, 1150 women with endometrial cancer underwent robotic-assisted laparoscopy (n=652), multiport laparoscopy (n=214), or single-port laparoscopy (n=284). The median age and body mass index of women was 62.0 years and 33.5 kg/m2, respectively. The majority of patients had endometrioid histology (88.1%), stage IA (74.7%) or IB disease (13.1%) and International Federation of Gynecology and Obstetrics grade 1 (57.4%) or 2 (26.0%) histology. Lymphovascular space invasion was present in 24.7% (n=283). Adjuvant radiation was given in 34.2% of cases, with 21.9% receiving vaginal brachytherapy, 6.6% pelvic radiation, and 5.4% both. For the entire cohort, there were no differences in progression-free survival at 2, 3, and 5 years for multiport laparoscopy (94.2%, 91.4%, 87.4%), robotic-assisted laparoscopy (94.5%, 92.9%, 88.8%), and single-port laparoscopy (93.6%, 91.2%, 90.0%) (P=.93), respectively. Similarly, there were no differences in overall survival at 2, 3, and 5 years for multiport laparoscopy (94.4%, 91.8%, 91.8%), robotic-assisted laparoscopy (95.6%, 93.4%, 90.7%), and single-port laparoscopy (95.0, 93.1, 91.8) (P=.99), respectively. Among women with stage IA and IB disease, no difference existed for progression-free survival at 2, 3, and 5 years for multiport laparoscopy (94.2%, 91.4%, 87.4%), robotic-assisted laparoscopy (94.5%, 92.9%, 88.8%), and single-port laparoscopy (93.6, 91.2, 90.0) (P=.93), respectively. Similarly, among women with stage I disease, there was no difference in overall survival at 2, 3, and 5 years for multiport laparoscopy (96.2%, 95.0%, 95.0%), robotic-assisted laparoscopy (96.6%, 95.4%, 93.3%), and single-port laparoscopy (96.6%, 95.0%, 93.4%) (P=.89). Rather, progression-free survival and overall survival were predicted by age >65 years, stage, grade, and histology (P<.05). On multivariate analysis, modality of surgery did not impact overall survival or progression-free survival (robotic-assisted laparoscopy, hazard ratio, 1.28, P=.50; single-port laparoscopy, hazard ratio, 0.84, P=.68 vs multiport laparoscopy). Age >65 years (hazard ratio, 5.42, P<.001) and advanced stage disease (P=.003) were associated with decreased overall survival. CONCLUSION: In this retrospective cohort, there was no difference in progression-free survival or overall survival in women undergoing surgery for endometrial cancer via robotic-assisted laparoscopy, single-port laparoscopy, or multiport laparoscopy.
引用
- Chambers LM, Carr C, Freeman L, et al. Does surgical platform impact recurrence and survival? A study of utilization of multiport, single-port, and robotic-assisted laparoscopy in endometrial cancer surgery. Am J Obstet Gynecol. 2019. PMID: 31075245. doi:10.1016/j.ajog.2019.04.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。